Question

Difficulty: HardPulmonary and Critical Care

A 5555-year-old woman is evaluated in the emergency department for severe shortness of breath that has worsened over the past 22 days. She has a history of asthma and hypertension. Her home medications include inhaled budesonide-formoterol and oral amlodipine. Over the last 1212 hours, she has been using her albuterol rescue inhaler every hour with minimal relief.

On initial presentation, she is in acute respiratory distress, using accessory muscles of respiration. Lung auscultation reveals diffuse expiratory wheezing. She has 1+1+ bilateral lower extremity pitting edema, which she states is her baseline. Initial treatment is initiated with oxygen, continuous nebulized albuterol and ipratropium, intravenous methylprednisolone, and intravenous magnesium sulfate.

Four hours later, the patient reports that her breathing is significantly easier. Her work of breathing has decreased, and wheezing is now faint and only audible at the lung bases. However, she now reports new-onset palpitations and hand tremors.

Current vital signs:
Temperature: 37.0∘C37.0^\circ\text{C} (98.6∘F98.6^\circ\text{F})
Blood pressure: 122/78 mm Hg122/78\text{ mm Hg}
Heart rate: 118/min118/\text{min}
Respiratory rate: 16/min16/\text{min}
SpO2: 96%96\% on room air

Laboratory evaluation reveals:
Serum sodium: 140 mEq/L140\text{ mEq/L}
Serum potassium: 3.6 mEq/L3.6\text{ mEq/L}
Serum chloride: 104 mEq/L104\text{ mEq/L}
Serum bicarbonate: 15 mEq/L15\text{ mEq/L}
Serum lactate: 4.8 mmol/L4.8\text{ mmol/L} (Normal: 0.50.5-1.0 mmol/L1.0\text{ mmol/L})

Arterial blood gas (room air):
pH: 7.327.32
PaCO2: 30 mm Hg30\text{ mm Hg}
PaO2: 84 mm Hg84\text{ mm Hg}

Which of the following is the most appropriate next step in management?

  1. Decrease the frequency of albuterol administrationAnswer
  2. B
    Perform endotracheal intubation
  3. C
    Administer intravenous piperacillin-tazobactam
  4. D
    Administer intravenous furosemide
  5. E
    Administer intravenous sodium bicarbonate

Answer

Decrease the frequency of albuterol administration
This patient has developed a high anion gap metabolic acidosis due to albuterol-induced Type B lactic acidosis. High doses of beta-2 agonists stimulate skeletal muscle beta-2 receptors, leading to increased cAMP, which heavily drives glycogenolysis and glycolysis. This excessive glycolytic flux generates massive amounts of pyruvate that overwhelm the TCA cycle's capacity, causing the excess pyruvate to be converted into lactate, even in the absence of tissue hypoxia. The patient's clinical improvement (decreased work of breathing, reduced wheezing, normalized respiratory rate) alongside classic beta-agonist side effects (tremor, palpitations) strongly points to this benign drug effect. Because the asthma is resolving, the most appropriate management is to simply decrease the frequency of albuterol administration. The lactic acidosis will self-resolve as the medication is cleared.

Step-by-Step Solution

1
Evaluate the patient's clinical trajectory.
The patient's work of breathing has decreased, wheezing is faint, and respiratory rate has normalized to 16/min, indicating the asthma exacerbation is resolving.
Clinical context is required to properly interpret the significance of abnormal laboratory findings.
2
Analyze the acid-base status.
The pH is 7.32 (acidemia) with a low bicarbonate of 15 mEq/L, indicating primary metabolic acidosis. Winter's formula (1.5 × 15 + 8) yields an expected PaCO2 of 28.5 to 32.5 mm Hg. The measured PaCO2 of 30 mm Hg is perfectly compensated.
Calculating expected compensation distinguishes between a compensated metabolic acidosis and an impending respiratory failure (mixed respiratory acidosis).
3
Determine the etiology of the metabolic acidosis.
The anion gap is 21 (140 - 104 - 15), confirming a high anion gap metabolic acidosis. The elevated lactate of 4.8 mmol/L explains the gap.
Identifying the unmeasured anion directs the specific therapy.
4
Integrate findings to establish the diagnosis and next step.
In a clinically improving asthma patient on high-dose beta-agonists who develops tremor, palpitations, and lactic acidosis, the diagnosis is albuterol-induced Type B lactic acidosis. The next step is to decrease the beta-agonist dose.
Albuterol drives glycogenolysis and glycolysis, producing excess pyruvate that converts to lactate without tissue hypoxia.

Key Concept

Albuterol-induced Type B lactic acidosis in severe asthma and the use of Winter's formula to confirm appropriate respiratory compensation.
Rate this question